首页 伊奥尼斯制药(usIONS)-基本信息

伊奥尼斯制药(usIONS)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:42.5

最高价:42.98

成交量:2121108.0

昨收价:42.69

最低价:41.49

最新价:42.36

行情图标
概要信息

中文名称:伊奥尼斯制药


英文名称:Ionis Pharmaceuticals


简介:伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位,利用新药研发平台,公司研发了大量的一流药品


电话:1-760-9319200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Ionis Pharmaceuticals, Inc.是一家生物制药公司,为其产品线和其合作伙伴从事以RNA为基础的药物的探索和开发。该公司的药物开发项目主要着眼于治疗心血管和代谢性疾病,以及癌症,炎症和其他疾病。Ionis Pharmaceuticals主要生产一种反义药物Vitravene,用于治疗艾滋病患者巨细胞病毒性视网膜炎。该公司及其合作夥伴正在开发大约18种药物,包括Mipomersen (ISIS 301012), ISIS 113715,ISIS 325568和ISIS 369645。该公司通过与Regulus Therapeutics LLC组成的一家合资企业,专注于微RNA疗法的开发和商业化。此外,2015年7月,伊奥尼斯制药还与阿斯利康(AZN)达成战略合作,將共同研发心血管、代谢和肾脏类疾病疗法。2017年7月14日,伊奥尼斯制药公司旗下专注于开发因脂质病症所引起的心脏代谢疾病治疗药物子公司——Akcea Therapeutics, Inc.成功IPO登陆纳斯达克。

交易日期 交易人 职位 类型 交易份额 价格
2017-07-23 Bennett (C Frank) Officer Buy 10000 10.29
2017-07-23 Bennett (C Frank) Officer Sell 10000 59.29
2017-07-19 Crooke (Stanley T) Chief Executive Officer Sell 1000 55.35
2017-07-19 Crooke (Stanley T) Chief Executive Officer Buy 1000 7.25
2017-07-19 Crooke (Stanley T) Chief Executive Officer Buy 10000 14.69
2017-07-19 Crooke (Stanley T) Chief Executive Officer Sell 10000 55.35
2017-07-16 Crooke (Stanley T) Chief Executive Officer Sell 1500 52.45
2017-07-16 Crooke (Stanley T) Chief Executive Officer Buy 15000 14.69
2017-07-16 Crooke (Stanley T) Chief Executive Officer Sell 15000 52.45
2017-07-16 Crooke (Stanley T) Chief Executive Officer Buy 1500 7.25
2017-07-02 Crooke (Stanley T) Chief Executive Officer Sell 1538 52.30
2017-07-02 Monia (Brett P) Officer Sell 309 51.35
2017-07-02 Crooke (Stanley T) Chief Executive Officer Sell 13462 52.08
2017-07-02 Crooke (Stanley T) Chief Executive Officer Buy 1538 14.69
2017-07-02 Crooke (Stanley T) Chief Executive Officer Buy 1500 7.25
2017-07-02 Crooke (Stanley T) Chief Executive Officer Buy 13462 7.25
2017-07-02 Crooke (Stanley T) Chief Executive Officer Sell 1500 52.10
2017-07-01 Klein (Joseph III) Director Buy 2469 --
2017-06-30 Bennett (C Frank) Officer Buy 253 40.66
2017-06-30 Geary (Richard S) Officer Buy 196 40.66
2017-06-30 Hougen Elizabeth L Chief Financial Officer Buy 104 40.66
2017-06-30 Muto (Frederick T) Director Buy 2469 --
2017-06-30 Boyce (Sarah) Officer Buy 17 40.66
2017-06-30 O Neil (Patrick R) General Counsel Buy 134 40.66
2017-06-30 Loscalzo (Joseph) Director Buy 2001 --
2017-06-30 Loscalzo (Joseph) Director Buy 2001 --
2017-06-30 Monia (Brett P) Officer Buy 163 40.66
2017-06-30 Wender (Joseph H) Director Buy 2469 --
2017-06-30 Parshall (B Lynne) Chief Operating Officer Buy 90 40.66
2017-06-30 Berthelsen (Spencer R) Director Buy 2469 --
第 页, 共 15 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Corporation 2553088 1.82% 17919 0.71% 2019-03-31
Vanguard Group Inc 12473515 8.89% 644127 5.45% 2019-03-31
ClearBridge Advisors, LLC 9498310 6.77% -882009 -8.50% 2019-03-31
Baillie Gifford & Co Limited. 8644351 6.16% -105663 -1.21% 2019-03-31
Bellevue Asset Management AG 8056558 5.74% 310558 4.01% 2019-07-31
BB Biotech AG 7725000 5.51% -1016334 -11.63% 2019-03-31
BlackRock Inc 7621572 5.43% -54685 -0.71% 2019-03-31
Wellington Management Company LLP 7539076 5.37% -87929 -1.15% 2019-03-31
Fidelity Management Trust Co 6281748 4.48% 3834 0.06% 2019-07-31
Hartford Funds Management Company, LLC 3636028 2.59% -99917 -2.67% 2019-07-31
Vanguard Investments Australia Ltd 3513996 2.50% 45388 1.31% 2019-07-31
Waddell & Reed Financial Inc 3362306 2.40% -135756 -3.88% 2019-03-31
Waddell & Reed Investment Management Co 3362306 2.40% -135756 -3.88% 2019-03-31
BlackRock Fund Advisors 3281415 2.34% 17164 0.53% 2019-07-31
Fidelity SelectCo, LLC 3009187 2.14% -84300 -2.73% 2019-07-31
First Trust Advisors L.P. 2591839 1.85% 370977 16.70% 2019-03-31
Legg Mason Partners Fund Advisor, LLC 2583005 1.84% -219025 -7.82% 2019-07-31
Fidelity Management & Research Company 12970992 9.24% -306616 -2.31% 2019-07-31
Fidelity Management and Research Company 20625098 14.70% 123948 0.60% 2019-03-31
FMR Inc 20633698 14.70% 123948 0.60% 2019-03-31
Geode Capital Management, LLC 2682866 1.91% 1423585 113.05% 2018-12-31
OppenheimerFunds Inc 2020126 1.47% -47474 -2.30% 2018-12-31
BlackRock Institutional Trust Company NA 3346939 2.43% -124333 -3.58% 2018-06-30
Biogen Idec Inc 11501153 9.16% 11501153 -- 2018-06-05
State Street Corp 3059018 2.23% 93771 3.16% 2018-06-30
Goldman, Sachs & Co. 1522888 1.11% -315884 -17.18% 2018-06-30
T. Rowe Price Associates, Inc. 1201633 0.88% -140299 -10.46% 2018-06-30
American Century Inv Mgt Inc 1185182 0.86% 6266 0.53% 2018-06-30
Wells Fargo Advisors, LLC 1178216 0.86% 67290 6.06% 2018-06-30
Legg Mason Investments Europe Ltd 1102130 0.80% -- -- 2018-07-31
Pinnacle Associates Inc 1243975 0.99% -45246 -3.51% 2018-03-31
Deutsche Bank AG 1034381 0.83% 968568 1471.70% 2017-09-30
Managed Account Advisors LLC 1332386 1.07% 512774 62.56% 2017-09-30
Altrinsic Global Advisors LLC 1033481 0.85% -337895 -24.64% --
Tocqueville Asset Management L.P. 1137549 0.94% -1514691 -57.11% --
Millennium Management LLC 1606306 1.33% 1606306 -- --
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
American Century Ultra 732904 0.52% -11096 -1.49% 2019-06-30
Fidelity Growth Company Commingled Pool 6233108 4.44% 3834 0.06% 2019-06-30
Vanguard Total Stock Market Index Fund 3463381 2.47% 74842 2.21% 2019-06-30
Vanguard Small Cap Index 3229595 2.30% -916 -0.03% 2019-06-30
Ivy Science and Technology Fund 2918326 2.08% -172300 -5.57% 2019-06-30
ClearBridge Aggressive Growth Fund 2342745 1.67% -205000 -8.05% 2019-06-30
Fidelity 2307785 1.64% -- -- 2019-06-30
Vanguard Health Care Fund 2224908 1.59% 105728 4.99% 2019-03-31
Hartford MidCap Fund 2027748 1.45% -- -- 2019-06-30
Vanguard Extended Market Index Fund 1929032 1.37% 22724 1.19% 2019-06-30
T. Rowe Price Health Sciences Fund 748909 0.53% -399100 -34.76% 2019-06-30
SPDR 909616 0.65% 17841 2.00% 2019-07-31
Baillie Gifford L/T Glb Gr Invmt Fd 916946 0.65% -- -- 2019-05-31
Invesco Oppenheimer Global Fund 1090906 0.78% -- -- 2019-06-30
First Trust NYSE Arca Biotech Fund 1380722 0.98% -3327 -0.24% 2019-07-31
iShares Nasdaq Biotechnology ETF 1385209 0.99% 14304 1.04% 2019-07-30
Vanguard Small Cap Growth Index Fund 1850550 1.32% 17637 0.96% 2019-06-30
Vanguard Small Cap Index Fund 3234881 2.31% 22307 0.69% 2019-04-30
Oppenheimer Global Fund 1090906 0.78% -- -- 2019-03-31
Legg Mason CB US Aggressive Growth Fund 782130 0.56% -105000 -11.84% 2019-03-31
First Trust Health Care AlphaDEX 807735 0.58% -- -- 2019-02-28
AZ InvestEd Ivy Science & Tech Fund 3217526 2.32% -316475 -8.96% 2018-12-31
Fidelity Advisor 719838 0.52% -- -- 2018-12-31
Waddell & Reed Advisor Science & Tech Fd 1965100 1.43% -- -- 2017-12-31
Vanguard Health Care Inv 2119180 1.55% -- -- 2018-06-30
Waddell & Reed Science & Tech A 1965100 1.57% -- -- 2017-12-31
ClearBridge Aggressive Growth A 2722745 1.98% -- -- 2018-07-31
Hartford MidCap A 2844496 2.07% -26654 -0.93% 2018-07-31
Vanguard Total Stock Mkt Idx 3149587 2.29% 20280 0.65% 2018-07-31
AZ InvestEd Ivy Science & Tech E 4180000 3.05% -- -- 2018-06-30
Vanguard Small Cap Growth Index Inv 1803163 1.31% 26390 1.49% 2018-07-31
Vanguard Extended Market Idx Inv 1663692 1.21% 15512 0.94% 2018-07-31
Hartford MidCap HLS IA 521339 0.38% -10814 -2.03% 2018-07-31
Hartford Capital Appreciation HLS IA 521558 0.38% -- -- 2018-07-31
Fidelity Spartan 568073 0.41% 8845 1.58% 2018-07-31
iShares Nasdaq Biotechnology 1423658 1.02% -2709 -0.19% 2018-09-12
Oppenheimer Global A 1545506 1.13% -- -- 2018-07-31
First Trust NYSE Arca Biotech ETF 1597470 1.15% -- -- 2018-09-13
Met Invt Ser ClearBridge Agrsv Gr E 498335 0.40% -- -- 2018-03-31
Hartford Growth Opportunities A 506572 0.40% -5550 -1.08% 2018-02-28
Hartford Capital Appreciation A 666890 0.53% -35610 -5.07% 2018-01-31

Stanley T. Crooke Founder of Ionis Pharmaceuticals, Inc., Stanley T. Crooke currently is Chairman, President & Chief Executive Officer at this company. He is also on the board of Biotechnology Innovation Organization and Symphony Genisis, Inc. In the past he held the position of President-Research & Development at Smithkline & French Laboratories US, Inc., President-Research & Development at Smithkline Beckman Corp, Professor at Baylor College of Medicine, Professor at Perelman School of Medicine and Professor at San Diego State University. He received a doctorate from Baylor College of Medicine and an undergraduate degree from Butler University.
Elizabeth L. Hougen Elizabeth L. Hougen is CFO, Principal Accounting Officer & SVP-Finance at Ionis Pharmaceuticals, Inc. In her past career she was CFO & Principal Accounting Officer for Akcea Therapeutics, Inc. and Chief Financial Officer & Executive Director at Molecular Biosystems, Inc. She received an MBA from the University of San Diego and an undergraduate degree from Franklin & Marshall College.
Joseph Loscalzo Dr. Joseph Loscalzo, MD PhD, is Advisor at Mi3 Venture Partners Management LLC. He is the Wade Professor and Chairman of the Department of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine, as well as Physician-in-Chief at Boston Medical Center. He is a founder of NitroMed, Inc., serves on its Board of Directors and chairs its Scientific Advisory Board. In 2004, he became Editor-in-Chief of Circulation, a leading cardiology scientific journal. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. He joined the Harvard faculty and staff at Brigham and Women's Hospital in 1984. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Chair of Medicine. Dr. Loscalzo is the immediate past Chair of the Cardiovascular Board of the American Board of Internal Medicine and immediate past Chair of the Board of Scientific Counselors of the NHLBI. He has been a Visiting Professor at many institutions and has authored or co-authored more than 400 scientific publications and 20 books. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past twenty years.
Richard S. Geary Richard S. Geary is Senior Vice President-Development at Ionis Pharmaceuticals, Inc. In his past career Dr. Geary occupied the position of Senior Research Scientist at Southwest Research Institute. Dr. Geary received an undergraduate degree from Texas A&M University and a doctorate from Ut College of Pharmacy.
Brett P. Monia Brett P. Monia founded Ionis Pharmaceuticals, Inc. He is Chief Operating Officer & Director at Ionis Pharmaceuticals, Inc., Member of American Association for Cancer Research, Member of American Society of Hematology, Member of American Association for The Study of Liver Diseases and Member of American Diabetes Association. He previously held the position of President at Oligonucleotide Therapeutics Society, Inc. Brett P. Monia received a doctorate from the University of Pennsylvania and an undergraduate degree from Stockton University.
Patrick R. O'Neil Presently, Patrick R. O'Neil holds the position of Secretary, Chief Compliance Officer & SVP-Legal at Ionis Pharmaceuticals, Inc. In the past he was Associate for Cooley LLP. He received an undergraduate degree from the University of San Francisco and a graduate degree from UC Davis School of Law.
Sarah Boyce Sarah Boyce is Chief Business Officer of Ionis Pharmaceuticals, Inc. In the past Ms. Boyce held the position of VP-Global & Head-Nephrology Therapeutics at Alexion Pharmaceuticals, Inc., Vice President-Global Program at Novartis AG and Vice President & Head-Business Strategy at Forest Laboratories, Inc. She received an undergraduate degree from The University of Manchester.
Joan Elizabeth Herman Joan Elizabeth Herman founded Herman & Associates LLC. Presently, she holds the position of President & Chief Executive Officer at Herman & Associates LLC and President at Fresenius Health Plans Insurance Co. Ms. Herman is also Member of The Society of Actuaries and Member of The American Academy of Actuaries and on the board of 6 other companies. She previously held the position of President & CEO-Consumer Business Unit at Anthem, Inc. and Executive Vice President for Wellpoint Health Networks, Inc. (a subsidiary of Anthem, Inc.), Executive Vice President for WellPoint Systems, Inc., Independent Director at MRV Communications, Inc. and Senior Vice President-Strategic Development at Nassau Life Insurance Co. She received a graduate degree from Yale University, an MBA from Western New England University and an undergraduate degree from Barnard College.
Joseph R. Klein Mr. Joseph R. Klein, III MBA, is Independent Director at Isis Pharmaceuticals, Inc. and Founder & Managing Director at Gauss Capital Advisors LLC. He is on the Board of Directors at Isis Pharmaceuticals, Inc., Gliknik, Inc., Shire Regenerative Medicine, Inc., and Prospector Funds, Inc. Prior to founding Gauss Capital Advisors, Mr. Klein was previously employed as Independent Director by Isis Pharmaceuticals, Inc., Venture Partner by Red Abbey Venture Partners LLC, Venture Partner by MPM Capital LP, Vice President-Strategy & Corporate Development by Medical Manager Corp., an Analyst by Federated Investment Management Co., Vice President by T. Rowe Price Associates, Inc., and a Portfolio Manager by Kaufmann Fund, Inc. He also served on the board at PDL BioPharma, Inc., OSI Pharmaceuticals, Inc., Savient Pharmaceuticals, Inc., Clinical Data, Inc., BioMarin Pharmaceutical, Inc., Genaissance Pharmaceuticals, Inc., Guilford Pharmaceuticals, Inc., and NPS Pharmaceuticals, Inc. Mr. Klein received his BA in Economics degree from Yale University and an MBA from Stanford University.
B. Lynne Parshall B. Lynne Parshall is on the board of Ionis Pharmaceuticals, Inc., Cytokinetics, Inc. and Akcea Therapeutics, Inc. and Member of Licensing Executives Society, Member of San Diego County Bar Association and Member of American Bar Association. Ms. Parshall previously held the position of Partner at Cooley LLP and Member of California State Bar Association. B. Lynne Parshall received an undergraduate degree from Harvard University and a graduate degree from Stanford Law School.
Joseph H. Wender Joseph H. Wender holds the position of Co-Chief Executive Officer & Partner at Colgin Cellars. Mr. Wender is also on the board of 6 other companies. Mr. Wender previously occupied the position of Partner at Goldman Sachs Bank Europe SE and Senior Managing Director at GSC Group (New Jersey). Mr. Wender received a graduate degree from Yale University, an MBA from Harvard University and an undergraduate degree from Northwestern University.
C. Frank Bennett C. Frank Bennett is Senior Vice President-Antisense Research at Ionis Pharmaceuticals, Inc. Dr. Bennett received an undergraduate degree from The University of New Mexico and a doctorate from Baylor College of Medicine.
Frederick T. Muto Frederick T. Muto is on the board of Ionis Pharmaceuticals, Inc. and Senior Counsel at Cooley LLP, Member of San Diego County Bar Association and Member of American Bar Association. He previously held the position of Member of California State Bar Association. He received a graduate degree from the University of California, Berkeley and an undergraduate degree from State University of New York at Buffalo.
Spencer R. Berthelsen Spencer R. Berthelsen is on the board of Ionis Pharmaceuticals, Inc. and St. Luke's Episcopal Hospital. In the past he was Chairman of Kelsey-Seybold Clinic, Professor at The University of Texas Health Science Center at Houston and Clinical Professor at Baylor College of Medicine.
Peter N. Reikes Peter N. Reikes is on the board of Ionis Pharmaceuticals, Inc. In the past he was Vice Chairman-Healthcare Investment Banking at Stifel, Nicolaus & Co., Inc., Principal at PaineWebber, Inc. and Vice Chairman at Cowen & Co. LLC. Peter N. Reikes received an MBA from the University of Pennsylvania and an undergraduate degree from the University of California, Los Angeles.
Michael R. Hayden Founder of Aspreva Pharmaceuticals Corp., Xenon Pharmaceuticals, Inc., Centre for Molecular Medicine & Therapeutic and NeuroVir Therapeutic, Inc., Michael R. Hayden is an entrepreneur who currently is Scientific Director at Canadian Genetics Diseases Network. He is also Member of American Society of Clinical Investigation, Professor at the University of British Columbia, Program Director at Translational Laboratory in Genetic Medicine and Director-Translational Laboratory at National University of Singapore and on the board of 7 other companies. In the past he was Chief Scientific Officer for Teva Pharmaceutical Industries Ltd., Director at Aspreva Pharmaceuticals Corp. and Director at Centre for Molecular Medicine & Therapeutic. Dr. Hayden received an undergraduate degree and a doctorate from the University of Cape Town.
Breaux B. Castleman Breaux B. Castleman is a businessperson who has been at the head of 6 different companies. Mr. Castleman is Chairman for MedaPoint, Inc. and President, Chief Executive Officer & Director at Syntiro Healthcare Services, Inc. He is also on the board of Ionis Pharmaceuticals, Inc., Fanfare Entertainment LLC, FemPartners, Inc. and Carden Transport Services LLC. In the past he was Chairman for STRATA Skin Sciences, Inc., Chief Executive Officer at Physia Corp., Chief Executive Officer for Kelsey-Seybold Clinic, President-Physician Resource Group at Caremark International, Inc. and President of Scripps Clinic Foundation. Mr. Castleman received an undergraduate degree from Yale University.
D. Wade Walke Presently, D. Wade Walke is VP-Corporate Communications & Investor Relations at Ionis Pharmaceuticals, Inc. In the past he held the position of Senior Director-Investor & Media Relations at Lexicon Pharmaceuticals, Inc.
Sanjay Bhanot Sanjay Bhanot holds the position of Chief Medical Officer at Ionis Pharmaceuticals, Inc. Dr. Bhanot received a doctorate from the University of British Columbia and a doctorate from the University of British Columbia.
Joseph Loscalzo Dr. Joseph Loscalzo, MD PhD, is Advisor at Mi3 Venture Partners Management LLC. He is the Wade Professor and Chairman of the Department of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine, as well as Physician-in-Chief at Boston Medical Center. He is a founder of NitroMed, Inc., serves on its Board of Directors and chairs its Scientific Advisory Board. In 2004, he became Editor-in-Chief of Circulation, a leading cardiology scientific journal. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. He joined the Harvard faculty and staff at Brigham and Women's Hospital in 1984. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Chair of Medicine. Dr. Loscalzo is the immediate past Chair of the Cardiovascular Board of the American Board of Internal Medicine and immediate past Chair of the Board of Scientific Counselors of the NHLBI. He has been a Visiting Professor at many institutions and has authored or co-authored more than 400 scientific publications and 20 books. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past twenty years.
Eugene Schneider Eugene Schneider is Vice President & Head-Clinical Development at Ionis Pharmaceuticals, Inc.
Damien McDevitt Damien McDevitt is on the board of Akcea Therapeutics, Inc. and Chief Business Officer for Ionis Pharmaceuticals, Inc. He previously occupied the position of Senior Vice President-Corporate Development for ACADIA Pharmaceuticals, Inc. and Vice President at GlaxoSmithKline LLC. Damien McDevitt received an undergraduate degree and a doctorate from Trinity College Dublin.
Steve Hughes Mr. Steve Hughes is a Chief Clinical Development Officer at Ionis Pharmaceuticals, Inc.

量化对比

全部评论 1

  • ARK Invest旗下自动&机器人技术ETF(ARKQ)增持3D系统55.89万股,增持22.5万股空白支票One(AONE)股票,增持18万股Raven Industries(RAVN)股票;此外,旗下基因进化ETF-ARK(ARKG)增持逾58.4万股Ionis Pharmaceuticals股票。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐